
David N Louis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6904320/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Paul Kleihues (1936–2022), neuropathology innovator and entrepreneur. Brain Pathology, 2022, 32, e13073.	4.1	0
2	Atretic cephalocele: Report of an infrequent dermatopathologic finding. Journal of Cutaneous Pathology, 2021, 48, 1439-1441.	1.3	1
3	Inhibitory CD161 receptor identified in glioma-infiltrating TÂcells by single-cell analysis. Cell, 2021, 184, 1281-1298.e26.	28.9	210
4	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology, 2021, 23, 1231-1251.	1.2	4,534
5	Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting. Archives of Pathology and Laboratory Medicine, 2020, 144, 196-206.	2.5	21
6	A half century of change in diagnostic neuropathology: from the giants of yore to current brain tumor classification. Human Pathology, 2020, 95, 161-168.	2.0	2
7	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. Journal of Infectious Diseases, 2020, 222, 1955-1959.	4.0	72
8	cIMPACTâ€NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathology, 2020, 30, 863-866.	4.1	168
9	Roses and rosettes—the two sides of James Homer Wright. Baylor University Medical Center Proceedings, 2020, 33, 286-292.	0.5	0
10	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathologica, 2020, 139, 603-608.	7.7	344
11	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	4.1	363
12	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell, 2019, 178, 835-849.e21.	28.9	1,408
13	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. Acta Neuropathologica, 2019, 137, 683-687.	7.7	170
14	Characterization of applicants for residency training in pathology: Does diversity exist?. Annals of Diagnostic Pathology, 2019, 40, 23-25.	1.3	3
15	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro-Oncology, 2019, 21, 596-605.	1.2	25
16	A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nature Communications, 2018, 9, 810.	12.8	56
17	cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathologica, 2018, 135, 639-642.	7.7	281
18	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 2018, 360, 331-335.	12.6	461

#	Article	IF	CITATIONS
19	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
20	A feast of reviews about brain and pituitary tumor pathology. Brain Tumor Pathology, 2018, 35, 49-50.	1.7	2
21	clMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathologica, 2018, 135, 481-484.	7.7	145
22	Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing. Seminars in Neurology, 2018, 38, 019-023.	1.4	30
23	PATH-32. BRAIN TUMOR CLASSIFICATION UPDATES FROM cIMPACT-NOW, THE CONSORTIUM TO INFORM MOLECULAR AND PRACTICAL APPROACHES TO CNS TUMOR CLASSIFICATION. Neuro-Oncology, 2018, 20, vi165-vi165.	1.2	0
24	RARE-08. GRADING CONSIDERATIONS FOR MENINGEAL SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA. Neuro-Oncology, 2018, 20, vi237-vi238.	1.2	1
25	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade №â€• Acta Neuropathologica, 2018, 136, 805-810.	7.7	599
26	Implementing the DICOM Standard for Digital Pathology. Journal of Pathology Informatics, 2018, 9, 37.	1.7	93
27	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	1.2	99
28	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro-Oncology, 2017, 19, 1380-1390.	1.2	35
29	The Utility of Expert Diagnosis in Surgical Neuropathology: Analysis of Consultations Reviewed at 5 National Comprehensive Cancer Network Institutions. Journal of Neuropathology and Experimental Neurology, 2017, 76, 189-194.	1.7	2
30	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science, 2017, 355, .	12.6	743
31	Announcing clMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica, 2017, 133, 1-3.	7.7	120
32	The 2016 WHO classification of central nervous system tumors: what neurologists need to know. Current Opinion in Neurology, 2017, 30, 643-649.	3.6	62
33	Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zülch, the WHO… and Shakespeare. Acta Neuropathologica, 2017, 134, 517-520.	7.7	15
34	Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. Neuro-Oncology, 2017, 19, 1640-1650.	1.2	54
35	cIMPACTâ€NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq1 1 0.784 27, 851-852.	4314 rgBT 4.1	/Overlock 10 63
36	Angioleiomyoma of the falx. Journal of Radiology Case Reports, 2016, 10, 8-15.	0.4	11

#	Article	IF	CITATIONS
37	Case 38-2016. New England Journal of Medicine, 2016, 375, 2381-2389.	27.0	3
38	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 2016, 131, 803-820.	7.7	12,144
39	Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. Neuro-Oncology, 2016, 19, now181.	1.2	17
40	Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004–2012, varying). Journal of Neuro-Oncology, 2016, 130, 31-42.	2.9	35
41	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature, 2016, 539, 309-313.	27.8	875
42	Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. Journal of Clinical Neuroscience, 2016, 31, 99-105.	1.5	8
43	The flowering of pathology as a medical discipline in Boston, 1892-c.1950: W.T. Councilman, FB Mallory, JH Wright, SB Wolbach and their descendants. Modern Pathology, 2016, 29, 944-961.	5.5	4
44	The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. Journal of Neuropathology and Experimental Neurology, 2016, 75, 4-18.	1.7	81
45	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Journal of the National Cancer Institute, 2016, 108, djv310.	6.3	182
46	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery, 2015, 5, 1164-1177.	9.4	821
47	The role of neuropathology in the management of patients with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 531-549.	2.9	120
48	Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncology, 2015, 1, 662.	7.1	68
49	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncology, 2015, 4, 287-294.	3.0	48
50	Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia. Modern Pathology, 2015, 28, 596-606.	5.5	55
51	Computational Pathology: An Emerging Definition. Archives of Pathology and Laboratory Medicine, 2014, 138, 1133-1138.	2.5	78
52	The 2013 symposium on pathology data integration and clinical decision support and the current state of field. Journal of Pathology Informatics, 2014, 5, 2.	1.7	14
53	Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells. Cell, 2014, 157, 580-594.	28.9	751
54	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nature Genetics, 2014, 46, 161-165.	21.4	408

#	Article	IF	CITATIONS
55	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology, 2014, 16, 1541-1546.	1.2	12
56	<scp>I</scp> nternational <scp>S</scp> ociety of <scp>N</scp> europathologyâ€ <scp>H</scp> aarlem <scp>C</scp> onsensus <scp>G</scp> uidelines for <scp>N</scp> ervous <scp>S</scp> ystem <scp>T</scp> umor <scp>C</scp> lassification and <scp>G</scp> rading. Brain Pathology, 2014, 24, 429-435.	4.1	499
57	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. Cancer Discovery, 2014, 4, 1299-1309.	9.4	207
58	Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science, 2014, 344, 1396-1401.	12.6	3,648
59	Association of PIK3CA-activating mutations with more disseminated disease at presentation and earlier recurrence in glioblastoma Journal of Clinical Oncology, 2013, 31, 2029-2029.	1.6	7
60	Update on Glioma Treatments in the United States. Japanese Journal of Neurosurgery, 2013, 22, 590-596.	0.0	0
61	The next step in brain tumor classification: "Let us now praise famous menâ€â€¦ or molecules?. Acta Neuropathologica, 2012, 124, 761-762.	7.7	35
62	An Ultra-High Speed Whole Slide Image Viewing System. Analytical Cellular Pathology, 2012, 35, 65-73.	1.4	9
63	Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss. Clinical Cancer Research, 2009, 15, 6430-6437.	7.0	88
64	The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica, 2007, 114, 97-109.	7.7	9,898
65	MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 97-117.	22.4	566
66	Glioma Test Array for Use with Formalin-Fixed, Paraffin-Embedded Tissue. Journal of Molecular Diagnostics, 2006, 8, 268-276.	2.8	43
67	Focus on central nervous system neoplasia. Cancer Cell, 2002, 1, 125-128.	16.8	130
68	Clear cell pleomorphic xanthoastrocytoma: case report. Acta Neuropathologica, 2001, 102, 404-408.	7.7	10
69	Adult Medulloblastoma: Prognostic Factors and Patterns of Relapse. Neurosurgery, 2000, 47, 623-632.	1.1	165
70	Multicolumn Infusion of Gene Therapy Cells into Human Brain Tumors: Technical Report. Neurosurgery, 2000, 46, 663-669.	1.1	19
71	Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Medicine, 1999, 5, 881-887.	30.7	309
72	Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathologica, 1998, 95, 287-290.	7.7	54

#	Article	IF	CITATIONS
73	Use of MIB-1 (Ki-67) Immunoreactivity in Differentiating Grade II and Grade III Gliomas. Journal of Neuropathology and Experimental Neurology, 1997, 56, 857-865.	1.7	86
74	Assignment of the human gene encoding eukaryotic initiation factor 4E (EIF4E) to the region q21-25 on chromosome 4. Somatic Cell and Molecular Genetics, 1997, 23, 221-223.	0.7	5
75	Evidence for Subarachnoid Spread in the Development of Multiple Meningiomas. Brain Pathology, 1995, 5, 11-14.	4.1	33
76	Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma. Journal of Neuropathology and Experimental Neurology, 1995, 54, 91-95.	1.7	306
77	Glioblastoma multiforme in four siblings: A cytogenetic and molecular genetic study. Journal of Neuro-Oncology, 1995, 24, 251-258.	2.9	15
78	The retinoblastoma gene is involved in malignant progression of astrocytomas. Annals of Neurology, 1994, 36, 714-721.	5.3	211
79	Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. Acta Neuropathologica, 1993, 86, 81-85.	7.7	93
80	Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis. Brain Pathology, 1993, 3, 19-26.	4.1	597